NASDAQ:BIOL - Nasdaq - US0909117022 - Common Stock - Currency: USD
TTM (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
---|---|---|---|---|---|---|---|---|
Revenue | 48.83M | 49.16M | 48.46M | 39.19M | 22.78M | |||
Cost Of Goods | 32.11M | 32.44M | 32.55M | 22.66M | 16.61M | |||
Gross Profit | 16.73M | 16.72M | 15.91M | 16.53M | 6.17M | |||
Operating Expenses | 33.89M | 34.66M | 41.25M | 32.65M | 24.71M | |||
Research and Development | 5.74M | 6.00M | 7.27M | 6.05M | 3.70M | |||
Selling, General, and Administrative Expenses | 28.16M | 28.66M | 33.98M | 26.60M | 21.01M | |||
Operating Income | -17.17M | -17.94M | -25.34M | -16.12M | -18.54M | |||
Interest Income/Expense | -2.88M | -2.71M | -3.19M | -2.68M | -2.38M | |||
Other Income/Expense | -1.18M | 48.00K | N/A | 0.00 | 4.22M | |||
Non Recurring Items | N/A | 0.00 | 0.00 | 2.70M | 0.00 | |||
Income Before Taxes | -21.22M | -20.60M | -28.53M | -16.09M | -16.70M | |||
Income Tax | 54.00K | 31.00K | 110.00K | 70.00K | 130.00K | |||
Net Income | -38.26M | -37.62M | -28.85M | -16.70M | -34.21M | |||
EBITDA | -13.86M | -15.14M | -24.84M | -15.72M | -18.04M | |||
Per Share Data | ||||||||
EPS Diluted Total Ops | -20.42 | -29.44 | -412.14 | -278.33 | -1.71K | |||
Non GAAP EPS | -14.25 | -31.89 | -410.00 | -3.25 | -8.75 | |||
Statistics | ||||||||
Gross Profit Margin | 34.26% | 34.02% | 32.83% | 42.18% | 27.09% | |||
Profit Margin | -78.35% | -76.52% | -59.53% | -42.61% | -150.18% | |||
Operating Profit Margin | -35.17% | -36.48% | -52.29% | -41.13% | -81.39% |
All data in USD